+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Hepatitis Therapeutics Market - Global Forecast 2026-2032- Product Image
Hepatitis Therapeutics Market - Global Forecast 2026-2032- Product Image
New

Hepatitis Therapeutics Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 195 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 5715892
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The hepatitis therapeutics market is evolving rapidly, shaped by advances in clinical science, dynamic regulatory frameworks, and shifts in commercial strategy. Senior healthcare decision-makers must adapt proactively to these changes to ensure sustained patient access and competitive positioning.

Market Snapshot

The Hepatitis Therapeutics Market expanded from USD 32.02 billion in 2025 to USD 33.47 billion in 2026 and is projected to reach USD 42.13 billion by 2032, reflecting a CAGR of 3.99%. Market momentum is driven by breakthrough oral regimens, evolving care delivery models, and heightened expectations for real-world value demonstration. These factors collectively prompt companies to refine portfolio strategies, optimize R&D investments, and fortify their market access approaches to align with new clinical and payer standards.

Scope & Segmentation

  • Therapeutic Class: Covers combination therapies, direct acting antivirals (DAAs), interferons, and nucleotide analogues, with DAAs including sub-classes like Ns3/4A protease inhibitors, Ns5A inhibitors, Ns5B polymerase inhibitors, and pan-genotypic regimens. These distinctions shape clinical positioning and evidence requirements.
  • Genotype Diversity: Addresses management differences among viral genotypes such as genotype 1 (with subtypes 1A and 1B) and other recognized genotypes. Response rates and treatment algorithms vary, influencing label claims and clinician engagement models.
  • Administration Routes: Details products delivered orally, intravenously, or subcutaneously. Administration characteristics impact adherence, convenience, and outpatient/inpatient treatment dynamics.
  • Distribution Channels: Examines pathways including hospital pharmacies, online pharmacies, and retail settings. Each channel presents unique access models and patient engagement opportunities.
  • Disease Stage: Distinguishes acute versus chronic infection stages, guiding intervention urgency, monitoring needs, and market positioning for rapid suppression versus long-term management.
  • Geographies: Analyzes regional variances across the Americas, EMEA, and Asia-Pacific, including differences in care infrastructure, regulatory expectations, and public health priorities.
  • Emerging Technologies: Explores diagnostics, monitoring solutions, digital adherence tools, and telehealth deployment that increasingly feature in hepatitis care pathways.

Key Takeaways

  • Recent breakthroughs in oral and combination regimens have reshaped treatment paradigms, demanding that commercial teams coordinate closely with regulatory and clinical counterparts to ensure uptake.
  • Manufacturers face shifting expectations from payers and health systems, who increasingly require comprehensive evidence including real-world outcomes, patient-reported data, and health economic analyses in product positioning.
  • Supply chain complexity has intensified as tariff measures drive companies to diversify sourcing, qualify new suppliers, and reinforce procurement practices, ensuring resilient operations and consistent patient access.
  • Segment-specific strategies unlock adoption: genotype-diverse products, flexible administration models, and channel-specific support solutions are critical in reaching both mainstream and niche patient populations.
  • Regional market dynamics compel tailored commercial approaches—ranging from centralized evidence submission in some EMEA markets to broad public health partnerships in Asia-Pacific and outcomes-driven value demonstration in the Americas.
  • Partnerships between biopharma innovators, service providers, and specialty pharmacies enhance post-launch evidence generation and patient engagement, supporting durable market access.

Tariff Impact

Market participants have adapted to the 2025 United States tariff measures by reevaluating procurement frameworks, accelerating supplier diversification, and establishing regional manufacturing or tolling arrangements. These adjustments require cross-functional collaboration and transparent contracting to ensure compliance, minimize costs, and support patient access. In response to increased acquisition costs and stricter payer controls, companies are prioritizing value-driven evidence generation and performance-based contracting.

Methodology & Data Sources

This report draws on a rigorous blend of systematic literature review, regulatory document analysis, clinical trial registry assessment, and structured interviews with clinicians, payers, and distribution partners. Synthesis of multiple data streams ensures accuracy and holistic insight across clinical efficacy, operational implications, and market trends.

Why This Report Matters

  • Enables leadership teams to develop robust strategies that address both clinical innovation and evolving payer requirements in hepatitis therapeutics.
  • Informs investment decisions by highlighting supply chain vulnerabilities, regional market differentiators, and evolving regulatory pathways.
  • Equips commercial and R&D leaders with actionable insights for navigating disruptions, engaging key stakeholders, and translating scientific advances into sustainable market success.

Conclusion

The hepatitis therapeutics market demands integrated strategies, supply chain resilience, and adaptive stakeholder engagement. Success hinges on aligning differentiation with operational excellence and evidence-driven access. Organizations that act decisively will be positioned for continued growth and patient impact.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Hepatitis Therapeutics Market, by Therapeutic Class
8.1. Combination Therapies
8.2. Direct Acting Antivirals
8.2.1. Ns3/4A Protease Inhibitors
8.2.2. Ns5A Inhibitors
8.2.3. Ns5B Polymerase Inhibitors
8.2.4. Pan Genotypic Regimens
8.3. Interferons
8.4. Nucleotide Analogues
9. Hepatitis Therapeutics Market, by Genotype
9.1. Genotype 1
9.1.1. Genotype 1A
9.1.2. Genotype 1B
9.2. Genotype 2
9.3. Genotype 3
9.4. Genotype 4
9.5. Genotype 5
9.6. Genotype 6
10. Hepatitis Therapeutics Market, by Route Of Administration
10.1. Injectable
10.1.1. Intravenous
10.1.2. Subcutaneous
10.2. Oral
11. Hepatitis Therapeutics Market, by Distribution Channel
11.1. Online
11.2. Offline
12. Hepatitis Therapeutics Market, by Stage Of Disease
12.1. Acute
12.2. Chronic
13. Hepatitis Therapeutics Market, by Region
13.1. Americas
13.1.1. North America
13.1.2. Latin America
13.2. Europe, Middle East & Africa
13.2.1. Europe
13.2.2. Middle East
13.2.3. Africa
13.3. Asia-Pacific
14. Hepatitis Therapeutics Market, by Group
14.1. ASEAN
14.2. GCC
14.3. European Union
14.4. BRICS
14.5. G7
14.6. NATO
15. Hepatitis Therapeutics Market, by Country
15.1. United States
15.2. Canada
15.3. Mexico
15.4. Brazil
15.5. United Kingdom
15.6. Germany
15.7. France
15.8. Russia
15.9. Italy
15.10. Spain
15.11. China
15.12. India
15.13. Japan
15.14. Australia
15.15. South Korea
16. United States Hepatitis Therapeutics Market
17. China Hepatitis Therapeutics Market
18. Competitive Landscape
18.1. Market Concentration Analysis, 2025
18.1.1. Concentration Ratio (CR)
18.1.2. Herfindahl Hirschman Index (HHI)
18.2. Recent Developments & Impact Analysis, 2025
18.3. Product Portfolio Analysis, 2025
18.4. Benchmarking Analysis, 2025
18.5. AbbVie Inc
18.6. Arbutus Biopharma Corporation
18.7. Assembly Biosciences Inc
18.8. AstraZeneca
18.9. Bayer AG
18.10. Biocon Limited
18.11. Blue Jay Therapeutics
18.12. Bristol Myers Squibb Company
18.13. Cipla Limited
18.14. Dr. Reddy's Laboratories Ltd
18.15. Dynavax Technologies Corporation
18.16. Enanta Pharmaceuticals Inc
18.17. F. Hoffmann-La Roche Ltd
18.18. Gilead Sciences Inc
18.19. GlaxoSmithKline plc
18.20. Hetero Healthcare Limited
18.21. Johnson & Johnson
18.22. Laurus Labs Limited
18.23. Lupin Limited
18.24. Merck & Co. Inc
18.25. NATCO Pharma Limited
18.26. Novartis International AG
18.27. Sun Pharmaceutical Industries Limited
18.28. Teva Pharmaceutical Industries Ltd
18.29. Zydus Lifesciences Ltd
List of Figures
FIGURE 1. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL HEPATITIS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL HEPATITIS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. UNITED STATES HEPATITIS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 13. CHINA HEPATITIS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY NS3/4A PROTEASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY NS3/4A PROTEASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY NS3/4A PROTEASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY NS5A INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY NS5A INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY NS5A INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY PAN GENOTYPIC REGIMENS, BY REGION, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY PAN GENOTYPIC REGIMENS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY PAN GENOTYPIC REGIMENS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY INTERFERONS, BY REGION, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY INTERFERONS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY INTERFERONS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY NUCLEOTIDE ANALOGUES, BY REGION, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY NUCLEOTIDE ANALOGUES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY NUCLEOTIDE ANALOGUES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, BY REGION, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, BY GROUP, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1A, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1A, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1A, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1B, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1B, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1B, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 2, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 2, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 2, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 3, BY REGION, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 3, BY GROUP, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 3, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 4, BY REGION, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 4, BY GROUP, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 4, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 5, BY REGION, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 5, BY GROUP, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 5, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 6, BY REGION, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 6, BY GROUP, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 6, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY ACUTE, BY REGION, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY ACUTE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY ACUTE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY CHRONIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY CHRONIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY CHRONIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 83. AMERICAS HEPATITIS THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 84. AMERICAS HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 85. AMERICAS HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2032 (USD MILLION)
TABLE 86. AMERICAS HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2032 (USD MILLION)
TABLE 87. AMERICAS HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2032 (USD MILLION)
TABLE 88. AMERICAS HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 89. AMERICAS HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 90. AMERICAS HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 91. AMERICAS HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2032 (USD MILLION)
TABLE 92. NORTH AMERICA HEPATITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 93. NORTH AMERICA HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 94. NORTH AMERICA HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2032 (USD MILLION)
TABLE 95. NORTH AMERICA HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2032 (USD MILLION)
TABLE 96. NORTH AMERICA HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2032 (USD MILLION)
TABLE 97. NORTH AMERICA HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 98. NORTH AMERICA HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 99. NORTH AMERICA HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 100. NORTH AMERICA HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2032 (USD MILLION)
TABLE 101. LATIN AMERICA HEPATITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 102. LATIN AMERICA HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 103. LATIN AMERICA HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2032 (USD MILLION)
TABLE 104. LATIN AMERICA HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2032 (USD MILLION)
TABLE 105. LATIN AMERICA HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2032 (USD MILLION)
TABLE 106. LATIN AMERICA HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 107. LATIN AMERICA HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 108. LATIN AMERICA HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 109. LATIN AMERICA HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2032 (USD MILLION)
TABLE 110. EUROPE, MIDDLE EAST & AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 111. EUROPE, MIDDLE EAST & AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 112. EUROPE, MIDDLE EAST & AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2032 (USD MILLION)
TABLE 113. EUROPE, MIDDLE EAST & AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2032 (USD MILLION)
TABLE 114. EUROPE, MIDDLE EAST & AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2032 (USD MILLION)
TABLE 115. EUROPE, MIDDLE EAST & AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 116. EUROPE, MIDDLE EAST & AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 117. EUROPE, MIDDLE EAST & AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 118. EUROPE, MIDDLE EAST & AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2032 (USD MILLION)
TABLE 119. EUROPE HEPATITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 120. EUROPE HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 121. EUROPE HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2032 (USD MILLION)
TABLE 122. EUROPE HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2032 (USD MILLION)
TABLE 123. EUROPE HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2032 (USD MILLION)
TABLE 124. EUROPE HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 125. EUROPE HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 126. EUROPE HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 127. EUROPE HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2032 (USD MILLION)
TABLE 128. MIDDLE EAST HEPATITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 129. MIDDLE EAST HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 130. MIDDLE EAST HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2032 (USD MILLION)
TABLE 131. MIDDLE EAST HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2032 (USD MILLION)
TABLE 132. MIDDLE EAST HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2032 (USD MILLION)
TABLE 133. MIDDLE EAST HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 134. MIDDLE EAST HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 135. MIDDLE EAST HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 136. MIDDLE EAST HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2032 (USD MILLION)
TABLE 137. AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 138. AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 139. AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2032 (USD MILLION)
TABLE 140. AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2032 (USD MILLION)
TABLE 141. AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2032 (USD MILLION)
TABLE 142. AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 143. AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 144. AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 145. AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2032 (USD MILLION)
TABLE 146. ASIA-PACIFIC HEPATITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 147. ASIA-PACIFIC HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 148. ASIA-PACIFIC HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2032 (USD MILLION)
TABLE 149. ASIA-PACIFIC HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2032 (USD MILLION)
TABLE 150. ASIA-PACIFIC HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2032 (USD MILLION)
TABLE 151. ASIA-PACIFIC HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 152. ASIA-PACIFIC HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 153. ASIA-PACIFIC HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 154. ASIA-PACIFIC HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2032 (USD MILLION)
TABLE 155. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 156. ASEAN HEPATITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 157. ASEAN HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 158. ASEAN HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2032 (USD MILLION)
TABLE 159. ASEAN HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2032 (USD MILLION)
TABLE 160. ASEAN HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2032 (USD MILLION)
TABLE 161. ASEAN HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 162. ASEAN HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 163. ASEAN HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 164. ASEAN HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2032 (USD MILLION)
TABLE 165. GCC HEPATITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 166. GCC HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 167. GCC HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2032 (USD MILLION)
TABLE 168. GCC HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2032 (USD MILLION)
TABLE 169. GCC HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2032 (USD MILLION)
TABLE 170. GCC HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 171. GCC HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 172. GCC HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 173. GCC HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2032 (USD MILLION)
TABLE 174. EUROPEAN UNION HEPATITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 175. EUROPEAN UNION HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 176. EUROPEAN UNION HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2032 (USD MILLION)
TABLE 177. EUROPEAN UNION HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2032 (USD MILLION)
TABLE 178. EUROPEAN UNION HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2032 (USD MILLION)
TABLE 179. EUROPEAN UNION HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 180. EUROPEAN UNION HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 181. EUROPEAN UNION HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 182. EUROPEAN UNION HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2032 (USD MILLION)
TABLE 183. BRICS HEPATITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 184. BRICS HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 185. BRICS HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2032 (USD MILLION)
TABLE 186. BRICS HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2032 (USD MILLION)
TABLE 187. BRICS HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2032 (USD MILLION)
TABLE 188. BRICS HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 189. BRICS HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 190. BRICS HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 191. BRICS HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2032 (USD MILLION)
TABLE 192. G7 HEPATITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 193. G7 HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 194. G7 HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2032 (USD MILLION)
TABLE 195. G7 HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2032 (USD MILLION)
TABLE 196. G7 HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2032 (USD MILLION)
TABLE 197. G7 HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 198. G7 HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 199. G7 HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 200. G7 HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2032 (USD MILLION)
TABLE 201. NATO HEPATITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 202. NATO HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 203. NATO HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2032 (USD MILLION)
TABLE 204. NATO HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2032 (USD MILLION)
TABLE 205. NATO HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2032 (USD MILLION)
TABLE 206. NATO HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 207. NATO HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 208. NATO HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 209. NATO HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2032 (USD MILLION)
TABLE 210. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 211. UNITED STATES HEPATITIS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 212. UNITED STATES HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 213. UNITED STATES HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2032 (USD MILLION)
TABLE 214. UNITED STATES HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2032 (USD MILLION)
TABLE 215. UNITED STATES HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2032 (USD MILLION)
TABLE 216. UNITED STATES HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 217. UNITED STATES HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 218. UNITED STATES HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 219. UNITED STATES HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2032 (USD MILLION)
TABLE 220. CHINA HEPATITIS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 221. CHINA HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 222. CHINA HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2032 (USD MILLION)
TABLE 223. CHINA HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2032 (USD MILLION)
TABLE 224. CHINA HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2032 (USD MILLION)
TABLE 225. CHINA HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 226. CHINA HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 227. CHINA HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 228. CHINA HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Hepatitis Therapeutics market report include:
  • AbbVie Inc
  • Arbutus Biopharma Corporation
  • Assembly Biosciences Inc
  • AstraZeneca
  • Bayer AG
  • Biocon Limited
  • Blue Jay Therapeutics
  • Bristol Myers Squibb Company
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd
  • Dynavax Technologies Corporation
  • Enanta Pharmaceuticals Inc
  • F. Hoffmann-La Roche Ltd
  • Gilead Sciences Inc
  • GlaxoSmithKline plc
  • Hetero Healthcare Limited
  • Johnson & Johnson
  • Laurus Labs Limited
  • Lupin Limited
  • Merck & Co. Inc
  • NATCO Pharma Limited
  • Novartis International AG
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd
  • Zydus Lifesciences Ltd

Table Information

Report AttributeDetails
No. of Pages195
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 33.47 Billion
Forecasted Market Value ( USD ) by 2032 $ 42.13 Billion
Compound Annual Growth Rate3.9%
Regions CoveredGlobal
No. of Companies Mentioned26

Related Topics

Related Reports

Antiviral Drugs for the Treatment of Hepatitis C Market - Global Forecast 2026-2032 - Product Image

Antiviral Drugs for the Treatment of Hepatitis C Market - Global Forecast 2026-2032

  • Report
  • 198 Pages
  • Global
From
Hepatitis Therapeutics - Global Strategic Business Report - Product Image

Hepatitis Therapeutics - Global Strategic Business Report

  • Report
  • 298 Pages
  • Global
From
Hepatitis Therapeutics Market Outlook 2025-2034: Market Share, and Growth Analysis - Product Image

Hepatitis Therapeutics Market Outlook 2025-2034: Market Share, and Growth Analysis

  • Report
  • 160 Pages
  • Global
From
Hepatitis C Market Report 2025 - Product Image

Hepatitis C Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Hepatitis Therapeutics Market Size, Share & Trends Analysis Report by Disease (Hepatitis a, Hepatitis B, Hepatitis C), Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies), and Region with Growth Forecasts, 2025-2033 - Product Image

Hepatitis Therapeutics Market Size, Share & Trends Analysis Report by Disease (Hepatitis a, Hepatitis B, Hepatitis C), Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies), and Region with Growth Forecasts, 2025-2033

  • Report
  • 150 Pages
  • Global
From

About the Hepatitis Drug Market

The Hepatitis Drug market is a subset of the Infectious Diseases Drugs market, which includes treatments for a variety of illnesses caused by microorganisms. Hepatitis drugs are used to treat viral infections of the liver, including hepatitis A, B, and C. These drugs can be used to reduce symptoms, prevent further damage to the liver, and even cure the infection. Common treatments include antiviral medications, interferon, and direct-acting antivirals. The Hepatitis Drug market is highly competitive, with many companies offering treatments for different types of hepatitis. Some of the major players in the market include AbbVie, Gilead Sciences, Merck, Bristol-Myers Squibb, and Novartis. Other companies such as Cipla, Mylan, and Teva Pharmaceuticals also offer treatments for hepatitis. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.